CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

TRIAMCINOLONE ACETONIDE

· ingredient triamcinoloneCorticosteroids· TRIAMCINOLONE ACETONIDE 1 mg/mL; TRIAMCINOLONE ACETONIDE .25 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.31654
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other triamcinolone products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
triamcinolone acetonide$0.07238−$0.24420
Dermavyx$0.08272−$0.23380
Triasil$0.11513−$0.20140
Triamcinolone Acetonide$0.18453−$0.13200
NYSTATIN AND TRIAMCINOLONE ACETONIDE$0.23054−$0.08600
triamcinolone acetonide$0.27895−$0.03760
nystatin and triamcinolone acetonide$0.28013−$0.03640
24 Hour Nasal Allergy$0.74946+$0.43290

Medicare Part D coverage · CY2026

On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 26% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.